pause, retrace, run...

So what's it going to be, boys and girls?

I'm easy with any of them. A pause and I'll wait, a retrace and I'll buy, a run and I'll put on my dancing shoes.

My personal view is it's dancing shoes time. For PAB to team up with Onyx, Onyx *must* have been given access to our clinical data - certainly from the first 3 cohorts and almost certainly from the unpublished 4th cohort. And they must have liked what they saw. As PeaceAKKI has pointed out numerous times, this makes it very likely that they're eyeing us up for a takeover (entire company) or a license deal for PAT-SM6. I sincerely doubt that the shareholders would allow a takeover as we have so many other products in the pipeline so I'm guessing at a license deal for big bucks. 1 billion isn't out of the question with ongoing royalties.

Next - the ASH conference is looming and our CEO is presenting our data there. She must be presenting data from the 4th cohort as they've already published the data from the previous trials so, to have their interest it follows that she'll be presenting the new stuff.

So my guess is that we'll see another announcement this week. If the SP looks like running out of puff I think that's when they'll drop the other shoe.

And, finally, we can forget about a CR in the near future as I'm pretty sure there's a shed-load of options that people an take up at around 5 cents. Excellent result for them and means it will fund us through to late next year...

So hang on to your hats. This is done yet by a long chalk